Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.22.4
Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Net sales $ 271,581 $ 269,276   $ 541,236 $ 526,995  
Operating income 67,891 62,348   124,208 125,570  
Costs recognized on sale of acquired inventory       (400) (1,596)  
Impact of partially owned consolidated subsidiaries(1)   8,114   (179) 8,748  
Eminence impairment         (18,715)  
Corporate general, selling, and administrative expenses (93,010) (100,693)   (192,386) (186,868)  
Total intangible assets, net 567,647     567,647   $ 531,522
Diagnostics and Genomics [Member]            
Restructuring costs     $ (1,185)     $ (242)
Operating Segments [Member]            
Operating income 97,632 104,161   192,212 201,725  
Costs recognized on sale of acquired inventory (100) (84)   (400) (1,595)  
Amortization of acquisition related intangible assets (19,125) (18,380)   (38,408) (36,769)  
Impact of partially owned consolidated subsidiaries(1)   (1,004)   647 (2,567)  
Acquisition related expenses and other 8,307 13,262   8,010 15,618  
Eminence impairment   (18,715)     (18,715)  
Stock based compensation, inclusive of employer taxes (16,878) (14,815)   (32,336) (28,675)  
Restructuring costs (780) (743)   (2,950) (1,928)  
Operating Segments [Member] | Protein Sciences [Member]            
Net sales 203,887 204,971   403,836 402,156  
Operating income 89,336 93,281   175,278 183,381  
Operating Segments [Member] | Diagnostics and Genomics [Member]            
Net sales 68,003 64,527   137,907 125,512  
Operating income 8,296 10,880   16,934 18,344  
Intersegment Eliminations [Member]            
Net sales (309) (222)   (507) (673)  
Corporate, Non-Segment [Member]            
Corporate general, selling, and administrative expenses $ (1,165) $ (1,334)   $ (2,567) $ (1,524)